I just worry about NASH data as lead for reasons I mentioned previoiusly. I would just prefer a pure play GLP
You're invested in VKTX for the GLP/GIP? Given that the data that come out are going to be 8 patients in a P1 dose escalation study, it has no relevance to the near-term future of the company.
Of course I've been saying that it's worth a buck of upside but apparently some people are thinking it actually has value now, given last week's weird fiasco
Market Data 
Markets 
AI
